Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. related to alleged violations of federal securities laws, particularly concerning misleading statements about the company's manufacturing and regulatory processes for its INO-3107 treatment [3][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Inovio to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Inovio, with a deadline of April 7, 2026, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Inovio and its executives made false statements regarding the manufacturing of the CELLECTRA device and the prospects of the INO-3107 Biologics License Application (BLA) [5]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 but indicated that the company did not provide sufficient information for accelerated approval [6]. - Inovio announced it does not plan to pursue approval under the standard review timeline and will seek a meeting with the FDA to discuss options for accelerated approval [6]. - Following the FDA's announcement, Inovio's stock price dropped by $0.56, or 24.45%, closing at $1.73 per share [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by March 2, 2026 [2][4]. Group 1: Allegations Against Agilon Health - The complaint alleges that agilon health and its executives made false and misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [4]. - It is claimed that the company overstated the financial benefits from strategic actions taken to mitigate risks, leading to materially false representations about its business and prospects [4]. - Following the release of disappointing second-quarter results on August 4, 2025, agilon health's stock plummeted by 51.5% on August 5, 2025, after the company suspended its full-year 2025 financial guidance [5]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased agilon health securities between February 26, 2025, and August 4, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest who is also typical of the class members, with the option for any class member to move the court for this role [6]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding agilon health's conduct [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pomdoctor Limited due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 13, 2026 [2][4]. Group 1: Allegations Against Pomdoctor - The complaint alleges that Pomdoctor and its executives made false and misleading statements and failed to disclose critical information, including involvement in a fraudulent stock promotion scheme and the use of offshore accounts for share dumping [4]. - Specific allegations include the omission of false rumors and artificial trading activity that inflated the stock price, leading to materially misleading statements about the company's business and prospects [4]. Group 2: Stock Performance - Pomdoctor's share price experienced a significant decline from approximately $0.50 per share on December 10, 2025, to about $0.38 per share on December 11, 2025, marking a drop of roughly $0.12 per share or approximately 24% in a single trading session [5]. - This decline was attributed to heightened volatility and selling pressure amid investor concerns regarding the company's financial performance and valuation [5]. Group 3: Legal Proceedings - The role of the lead plaintiff in the class action is to represent the interests of the class members, and any member can apply to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]. - Faruqi & Faruqi encourages individuals with information regarding Pomdoctor's conduct to come forward, including whistleblowers and former employees [7].

Core Viewpoint - Rosen Law Firm is reminding former stockholders of Smartsheet Inc. about a class action lawsuit related to the January 2025 sale of Smartsheet to a consortium including Blackstone, Vista Equity Partners, and Platinum Falcon, with a lead plaintiff deadline of February 24, 2026 [1]. Group 1: Class Action Details - Former Smartsheet stockholders may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The complaint alleges that Smartsheet's solicitation of stockholder approval for the Buyout involved a false and misleading Proxy statement that misrepresented the company's financial performance [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience [4]. - Rosen Law Firm has a history of successful settlements in securities class actions, including significant recoveries for investors [4].

Earnings Expectations - Richtech Robotics Inc. (NASDAQ:RR) is expected to report an earnings per share (EPS) of -$0.02 and revenue of approximately $2.34 million for the upcoming quarter on February 13, 2026 [1][6]. Legal Proceedings - Investors are reminded of the April 3, 2026, deadline to apply for the lead plaintiff role in the ongoing federal securities class action against RR, which is crucial for directing litigation strategies [2][6]. Financial Health - The company faces challenges with a negative price-to-earnings (P/E) ratio of -38.81 and a high price-to-sales ratio of 109.02, indicating a premium price paid by investors for each dollar of sales [3][6]. - Despite these financial hurdles, RR maintains a minimal debt-to-equity ratio of 0.0027, indicating low reliance on debt financing, and a high current ratio of 107.45, suggesting strong liquidity [5][6]. - The enterprise value to sales ratio is at 70.78, while the enterprise value to operating cash flow ratio is -39.49, highlighting negative cash flow [4].

Core Viewpoint - SLM Corporation is facing a federal securities class action due to allegations of making false and misleading statements regarding its financial health, particularly concerning increasing early-stage delinquencies and the effectiveness of its loss mitigation programs [1] Group 1: Allegations Against SLM Corporation - The complaint alleges that SLM and its executives violated federal securities laws by failing to disclose a significant increase in early-stage delinquencies [1] - Defendants are accused of overstating the effectiveness of SLM's loss mitigation and loan modification programs, as well as the overall stability of the Company's PEL delinquency rates [1] - Public statements made by the defendants created a materially false and misleading impression regarding SLM's business operations and prospects [1] Group 2: Impact of TD Cowen's Report - On August 14, 2025, TD Cowen reported that July 2025 delinquencies increased by 49 basis points month-over-month, which was worse than the seasonal increase of 10 basis points [1] - The report highlighted a 45 basis point increase in early-stage delinquencies, contradicting previous assurances from SLM's executives that delinquency rates were following normal seasonal trends [1] - Following the report, SLM's stock price dropped by $2.67 per share, or 8.09%, closing at $30.32 per share on August 15, 2025 [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SLM Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's financial health and delinquency rates [2][4]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses in SLM between July 25, 2025, and August 14, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against SLM, with a deadline of February 17, 2026, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that SLM and its executives made false statements regarding the company's delinquency rates and the effectiveness of its loss mitigation programs [4]. Group 2: Financial Performance and Market Reaction - A report from TD Cowen on August 14, 2025, indicated that July 2025 delinquencies increased by 49 basis points month-over-month, which was significantly worse than the seasonal expectation of a 10 basis point increase [5]. - Following the TD Cowen report, SLM's stock price dropped by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [5]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Plug Power Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about funding and project viability [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Plug Power between January 17, 2025, and November 13, 2025, to discuss their legal options [1]. - There is a deadline of April 3, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Plug Power [2]. - The complaint alleges that Plug Power and its executives made false statements regarding the availability of funds from the DOE Loan and the company's project plans [4]. Group 2: Executive Changes and Market Reaction - On October 7, 2025, Plug Power announced the resignation of CEO Andrew Marsh and President Sanjay Shrestha, with Jose Luis Crespo appointed to both roles, which raised concerns about the company's stability [5]. - Following the announcement of executive changes, Plug Power's stock price fell by $0.26 per share, or 6.29%, closing at $3.87 [6]. - On November 10, 2025, Plug Power reported financial results indicating a significant pivot in strategy, including the suspension of activities under the DOE loan program, which had not been previously disclosed [7]. Group 3: Financial Performance and Stock Price Impact - After the financial results announcement, Plug Power's stock price dropped by $0.09 per share, or 3.39%, closing at $2.53 on November 11, 2025 [8]. - Following a report confirming the suspension of plans to construct hydrogen production facilities, Plug Power's stock price fell by $0.48 per share, or 17.58%, closing at $2.25 on November 14, 2025 [9].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Simulations Plus, Inc. due to allegations of materially misleading business information issued to the public [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Simulations Plus securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Company Performance and Market Reaction - On July 15, 2025, an article published by Benzinga reported that Simulations Plus experienced weaker demand, leading to a decline in stock price [3]. - The company reported sales of $20.4 million for the third quarter of 2025, which was a 10% year-over-year increase but fell short of the consensus estimate of $20.9 million [3]. - Preliminary sales figures released in June indicated lower expectations, with estimates ranging from $19 million to $20 million, compared to a consensus of $22.78 million [3]. - Following the news, Simulations Plus stock fell by 25.75% on July 15, 2025 [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bath & Body Works, Inc. due to allegations of violations of federal securities laws, encouraging affected investors to contact them for legal options [2][4]. Group 1: Legal Investigation - The law firm is looking into claims against Bath & Body Works for misleading statements and failure to disclose critical information regarding the company's growth strategy and financial performance [4]. - Investors who purchased securities in Bath & Body Works between June 4, 2024, and November 19, 2025, and suffered losses exceeding $50,000 are encouraged to reach out to the firm [1][2]. Group 2: Allegations Against the Company - The complaint alleges that the company's strategy of pursuing "adjacencies, collaborations, and promotions" did not effectively grow the customer base or deliver the expected net sales growth [4]. - It is claimed that as the company's strategy faltered, it relied on brand collaborations to mask weak financial results, leading to a failure to meet previously issued financial guidance [4]. - The positive statements made by the company regarding its business and prospects are described as materially misleading and lacking a reasonable basis [4]. Group 3: Class Action Details - A federal securities class action has been filed against Bath & Body Works, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2][5]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]. Group 4: Call for Information - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Bath & Body Works' conduct [6].